MetaCap

Avalyn Pharma (AVLN) vs Ocular Therapeutix (OCUL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Avalyn Pharma is the larger company by market cap ($1.26 billion vs $1.23 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AVLN-3.70%OCUL-40.55%
+37%-4%-44%
Apr 30, 20261 yearNov 20, 2026
AVLN-4.83%OCUL-40.93%
+35%-5%-45%
Apr 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AVLN versus OCUL key metrics
MetricAVLNOCUL
Share price$28.40$5.57
Market cap$1.26B$1.23B
1-day change-1.05%-4.95%
YTD return—-54.12%
1-year return—-54.49%
5-year return—-14.83%
EPS (TTM)$-3.96$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$51.95M
Revenue growth (YoY)—-18.47%
Net income (latest FY)—$-265.94M
Gross margin—87.35%
Operating margin—-519.75%
Net margin—-511.90%
52-week high$40.17$16.44
52-week low$22.24$5.54
Distance from 52-week high-29.30%-66.12%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+114.79%+361.94%
Average volume352.95K3.03M
Shares outstanding44.52M220.02M
Employees56325
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Avalyn Pharma

AVLN stock →

Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees

About Ocular Therapeutix

OCUL stock →

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 325 employees

AVLN vs OCUL FAQ

Which is bigger, Avalyn Pharma or Ocular Therapeutix?

Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.26B compared with $1.23B for Ocular Therapeutix (OCUL).

Are Avalyn Pharma and Ocular Therapeutix in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons